Skip to main content
Figure 2 | Cancer Cell International

Figure 2

From: Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent

Figure 2

Efficacy of VSVΔ51 combined with RT or ZD6126 in the FaDu xenograft model. (A) FaDu xenograft tumours were established im in the left leg of CD-1 nude mice to allow for local RT delivery. Mice were then randomized to six groups: a) UV-inactivated VSVΔ51 (1 × 109 pfu i.v.); (b) local tumour RTx2 (5 Gy), 3 days apart; (c) VSVΔ51 (1 × 109 pfu i.v.); (d) RT (5 Gy each) plus VSVΔ51 (1 × 109 pfu i.v.) simultaneously, then 2nd RT (5 Gy) delivered 3 days later; (e) ZD6126 alone (5 mg i.v. in 200 μl); and (f) ZD6126 (5 mg) just preceding 1 × 109 VSVΔ51 i.v. Data are presented as mean leg plus tumour diameter ± S.E. (B) Mice in panel (A) were monitored for survival for up to 70 days. All p-values were calculated using the Two-Way ANOVA analysis in comparison with the UV-inactivated VSV control group; survival comparisons were conducted using the log-rank test. n.s., not significant, *p≤0.05,** p≤0.005, ***p≤0.0005.

Back to article page